{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:23:29Z","timestamp":1785417809308,"version":"3.56.0"},"reference-count":25,"publisher":"Wiley","issue":"20","license":[{"start":{"date-parts":[[2013,8,6]],"date-time":"2013-08-06T00:00:00Z","timestamp":1375747200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2013,10,15]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Stem cell transplant (SCT)\u2010related outcomes and prognostication for relapsed\/refractory follicular lymphoma (FL) are not well\u2010defined in the post\u2010rituximab era.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Through the National Comprehensive Cancer Network (NCCN) lymphoma outcomes study, 184 patients with relapsed\/refractory FL who underwent autologous SCT (autoSCT) or allogenic SCT (alloSCT) following disease relapse after prior rituximab\u2010based therapy were examined.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Patients who underwent autoSCT (N\u2009=\u2009136) were older compared with patients who underwent alloSCT (N\u2009=\u200948) (54 versus 51 years, respectively, <jats:italic>P<\/jats:italic>\u2009=\u2009.01) and more frequently had grade 3 FL (35% versus 8%, respectively, <jats:italic>P<\/jats:italic>\u2009=\u2009.006). Patients who underwent alloSCT received more prior therapies (4 versus 3, respectively, <jats:italic>P<\/jats:italic>\u2009&lt;\u2009.0001) and more often had resistant disease at SCT (19% versus 6%, respectively, <jats:italic>P<\/jats:italic>\u2009=\u2009.008). Cumulative 100\u2010day nonrelapse mortality (NRM) for autoSCT and alloSCT were 1% and 6%, respectively (<jats:italic>P<\/jats:italic>\u2009&lt;\u2009.0001), whereas 3\u2010year NRM rates were 3% versus 24%, respectively (<jats:italic>P<\/jats:italic>\u2009&lt;\u2009.0001). For autoSCT and alloSCT, cumulative rates of relapse, progression, and\/or transformation were 32% versus 16%, respectively (<jats:italic>P<\/jats:italic>\u2009=\u2009.03), whereas 3\u2010year overall survival rates were 87% versus 61% (<jats:italic>P<\/jats:italic>\u2009&lt;\u2009.0001); there were no differences in failure\u2010free survival. AlloSCT was associated with increased risk of death on multivariate analysis (hazard ratio\u2009=\u20092.77, 95% confidence interval\u2009=\u20091.46\u20105.26, <jats:italic>P<\/jats:italic>\u2009=\u2009.002). This finding persisted on propensity scoring\/matching. Multivariate analysis for autoSCT patients identified age\u2009&gt;\u200960 years and\u2009&gt;\u20093 prior therapies as adverse factors. Furthermore, a survival model was created for the autoSCT cohort based on number of factors present (0, 1, 2); 3\u2010year failure\u2010free survival was 72%, 47%, and 20%, respectively (<jats:italic>P<\/jats:italic>\u2009=\u2009.0003), and 3\u2010year overall survival was 96%, 82%, and 62%, respectively (<jats:italic>P<\/jats:italic>\u2009&lt;\u2009.0001).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>AutoSCT remains an effective therapy for patients with FL. For alloSCT, continued strategies to reduce NRM are needed. <jats:bold><jats:italic>Cancer<\/jats:italic> 2013;119:3662\u20133671<\/jats:bold>. \u00a9 <jats:italic>2013 American Cancer Society<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.28243","type":"journal-article","created":{"date-parts":[[2013,8,6]],"date-time":"2013-08-06T16:31:10Z","timestamp":1375806670000},"page":"3662-3671","source":"Crossref","is-referenced-by-count":64,"title":["Stem cell transplantation for follicular lymphoma relapsed\/refractory after prior rituximab"],"prefix":"10.1002","volume":"119","author":[{"given":"Andrew M.","family":"Evens","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology Tufts University School of Medicine Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Vanderplas","sequence":"additional","affiliation":[{"name":"Department of Biostatistics City of Hope National Medical Center Duarte California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann S.","family":"LaCasce","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison L.","family":"Crosby","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auayporn P.","family":"Nademanee","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplant City of Hope National Medical Center Duarte California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Kaminski","sequence":"additional","affiliation":[{"name":"University of Michigan Cancer Center Ann Arbor Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Abel","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Millenson","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron S.","family":"Czuczman","sequence":"additional","affiliation":[{"name":"Roswell Park Cancer Institute Buffalo New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Niland","sequence":"additional","affiliation":[{"name":"Department of Biostatistics City of Hope National Medical Center Duarte California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Zelenetz","sequence":"additional","affiliation":[{"name":"Memorial Sloan\u2010Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo I.","family":"Gordon","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology Northwestern University Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology University of Rochester, James P. Wilmot Cancer Center Rochester New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,8,6]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008399623564"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.8327"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.023"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.2.404"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr450"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.11.004"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-369629"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4061"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/b97377"},{"key":"e_1_2_7_12_1","volume-title":"Analysing Survival Data from Clinical Trials and Observational Studies","author":"Marubini E","year":"1995"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1214\/aos\/1176350951"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1984.10478078"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3150"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.5358"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.00.8524"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.05.035"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.4204"},{"issue":"15","key":"e_1_2_7_20_1","doi-asserted-by":"crossref","first-page":"abstract 8005","DOI":"10.1200\/jco.2010.28.15_suppl.8005","article-title":"Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high\u2010dose therapy as in vivo purging and to maintain remission following high\u2010dose therapy","volume":"28","author":"Pettengell R","year":"2010","journal-title":"J Clin Oncol"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr498"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.030320"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705849"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-136242"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.017608"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.9100"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.28243","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.28243","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:47:34Z","timestamp":1760258854000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.28243"}},"subtitle":["A comprehensive analysis from the NCCN lymphoma outcomes project"],"short-title":[],"issued":{"date-parts":[[2013,8,6]]},"references-count":25,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2013,10,15]]}},"alternative-id":["10.1002\/cncr.28243"],"URL":"https:\/\/doi.org\/10.1002\/cncr.28243","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,6]]}}}